Cancer Stem Cells Therapy Market Size - By Type (Targeted Cancer Stem Cells, Stem Cells-based), Cancer Type (Breast, Lung, Colorectal, Prostrate), End-user, Global Forecast (2023- 2032)

Description

List of Tables

Global Cancer Stem Cells Therapy Market will witness 10.2% CAGR between 2023 and 2032, propelled by burgeoning research and development endeavors. These efforts, focusing on innovative therapeutics and treatments, aim to unravel the complexities of cancer at its core. For instance, in November 2023, in a Genes & Diseases review, ICMR-National Institute of Nutrition experts proposed the repurposing of non-cancer drugs to target elusive cancer stem cells (CSCs). This strategy taps into approved drugs with proven safety for other conditions, offering a safer and quicker path to innovate cancer therapy. CSCs, crucial in determining tumor aggressiveness and resisting standard treatments, underscore the need for more customized therapies. This breakthrough paves the way for tailored cancer treatments.

With an ardent pursuit of breakthrough discoveries, the field witnesses an unprecedented surge, driving the demand for targeted therapies and precision medicine. This surge in exploration and innovation not only amplifies therapeutic options but also underscores the critical role of the cancer stem cells therapy market outlook in revolutionizing cancer treatment paradigms.

The overall Cancer Stem Cells Therapy Market is classified based on cancer type, end-user, and region.

Colorectal cancer segment will undergo significant development from 2023 to 2032. With its prevalence and challenging nature, colorectal cancer underscores the necessity for innovative therapies targeting cancer stem cells. As research unravels the intricacies of these cells' role in tumor aggressiveness and resistance, the market responds with a growing need for precision therapies, elevating the significance of cancer stem cells therapy market share in addressing colorectal cancer.

Specialty centers segment will register a noteworthy CAGR from 2023 to 2032. These centers, renowned for their expertise and cutting-edge technology, fuel the demand for innovative therapies targeting cancer stem cells. As they pioneer new approaches and demonstrate improved outcomes, the market witnesses a surge in demand for these specialized treatments, highlighting the pivotal role of specialty centers in shaping the cancer stem cells therapy market outlook.

Asia Pacific cancer stem cells therapy industry will showcase a commendable CAGR from 2023 to 2032. With a rising prevalence of cancer, especially in countries like China and India, there's a growing need for innovative therapies targeting cancer stem cells. As research and development expand in this region, coupled with a focus on personalized medicine, the market witnesses a surge in demand for tailored treatments, shaping the cancer stem cells therapy landscape in Asia-Pacific.

For instance, in November 2023, a study by Hokkaido University's Institute for Genetic Medicine, led by Associate Professor Haruka Wada, delved into how cancer stem cells evade the immune system in mouse models, triggering aging in macrophages. These immune cells typically initiate cancer cell death but were shown to undergo senescence due to the influence of cancer stem cells. The Journal for ImmunoTherapy of Cancer published their discoveries.

Product Code: 7152

Chapter 1 Methodology & Scope

1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Global cancer stem cells therapy market 360 degree synopsis, 2018 - 2032
2.2 Business trends
2.3 Region trends
2.4 Type trends
2.5 Cancer type trends
2.6 End-user trends

Chapter 3 Cancer Stem Cells Therapy Industry Insights

3.1 Industry landscape, 2018 - 2032 (USD Million)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing cases of cancer
  - 3.2.1.2 Increasing private and public initiatives
  - 3.2.1.3 Rising awareness regarding availability of stem cell therapy
  - 3.2.1.4 Increasing research & development programs
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Associated side-effects
  - 3.2.2.2 High cost of stem cell therapy
3.3 Growth potential analysis
- 3.3.1 By type
- 3.3.2 By cancer type
- 3.3.3 By end-user
3.4 COVID-19 impact analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players,
4.4 Competitive positioning matrix, 2022
4.5 Strategic dashboard, 2022

Chapter 5 Cancer Stem Cells Therapy Market Size and Forecast, By Type, 2018-2032 (USD Million)

5.1 Key trends, by type
5.2 Targeted cancer stem cells
5.3 Stem cells-based therapy
- 5.3.1 Allogenic stem cell
- 5.3.2 Autologous stem cell

Chapter 6 Cancer Stem Cells Therapy Market Size and Forecast, By Cancer Type 2018-2032 (USD Million)

6.1 Key trends, by cancer type
6.2 Breast
6.3 Lung
6.4 Colorectal
6.5 Prostrate
6.6 Stomach
6.7 Liver
6.8 Other cancer types

Chapter 7 Cancer Stem Cells Therapy Market Size and Forecast, By End-user, 2018-2032 (USD Million)

7.1 Key trends, by end-user
7.2 Hospitals
7.3 Specialty centres
7.4 Other end-users

Chapter 8 Cancer Stem Cells Therapy Market Size and Forecast, By Region, 2018-2032 (USD Million)

8.1 Key trends, by region
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Italy
- 8.3.5 Spain
- 8.3.6 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East & Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 Rest of Middle East & Africa

Chapter 9 Company Profiles

9.1 Gamida Cells
9.2 AbbVie Inc
9.3 Astellas Pharma Inc
9.4 Novadip Biosciences
9.5 ReNeuron Group plc
9.6 Celyad
9.7 Adna GmBH
9.8 Thermo Fisher Scientific
9.9 Genentech Inc
9.10 Merck KGaA